Optimised Heterologous Expression and Functional Analysis of the

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Anti-infective compounds forSustainable microbiology · 2026
   Review
2. Glycyrrhizin (GLY) and glycyrrhetinic acid (GA) as potential multi-target antimicrobials: mechanisms, biofilm disruption, and synergy against drug-resistant pathogens.Frontiers in microbiology · 2026
   Review
3. Targeting MarA N-terminal domain dynamics to prevent DNA binding.Protein science : a publication of the Protein Society · 2025
   Article
4. Diversity in Genetic Regulation of Bacterial Fimbriae Assembled by the Chaperone Usher Pathway.International journal of molecular sciences · 2022
   Review
5. Unraveling the molecular determinants of the anti-phagocytic protein cloak of plague bacteria.PLoS pathogens · 2022
   Article
6. MsmR1, a global transcription factor, regulates polymyxin synthesis and carbohydrate metabolism inFrontiers in microbiology · 2022
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

Indexed as